Moderna’s stock plummeted by 18% on Friday after the biotech giant announced a significant reduction in its 2025 sales forecast.Â
The company now projects annual sales between $1.5 billion and...
Humacyte, Inc. (NASDAQ: HUMA), a pioneering biotechnology company specializing in bioengineered human tissues, has experienced a significant surge in...